JaredGollobMD

specialization is Internal Medicine - Hematology & Oncology at Duke University Medical Ctr

Are you Dr. Gollob?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. Jared Gollob, MD is a hematologist in Durham, North Carolina. He is currently licensed to practice medicine in Massachusetts.

PubMed

1561 citations
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams, Alejandra González-Duarte, William O'Riordan, Chih-Chao Yang, Mitsuharu Ueda
The New England Journal of Medicine. 2018-07-05
222 citations
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr, Teresa Coelho, Juan Buades, Jean Pouget, Isabel Conceição
Orphanet Journal of Rare Diseases. 2015-09-04
123 citations
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
David Adams, Ole B. Suhr, Peter J. Dyck, William J. Litchy, Raina G. Leahy
BMC Neurology. 2017-09-11

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253May 19th, 2023
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical TrialsDecember 14th, 2022
Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual MeetingMay 3rd, 2021
Join now to see all